StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
TEM$49.86+0.00%
Fair $49.86+0.0%

TEM

Tempus AI, Inc.

Healthcare / Health Information ServicesNasdaqGS

$49.86

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $49.86Fund rank 27/100 · Data gapFallback financials|
SA 11/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-239.1M · quality 57.7/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

11/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -49.9%, below the 5% threshold
Thesis & Journal · TEMLocal privado en este navegador · Tempus AI, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9.0B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-49.9%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+58.3%

FCF CAGR

—

FCF margin

-18.8%

FCF / Net income

0.98x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.27B · net income $-245.0M · FCF $-239.1M

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

-19.9%+62.9% pts

Net margin

-19.3%+71.1% pts

FCF margin

-18.8%+39.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.27B$1.27B$693.4M$531.8M$320.7M
Net Income$-245.0M$-245.0M$-705.8M$-214.1M$-289.8M
EPS-1.41-1.41-6.23-4.20-5.30
Operating Margin-19.9%-19.9%-99.7%-36.9%-82.8%
Net Margin-19.3%-19.3%-101.8%-40.3%-90.4%
Cash Flow
Free Cash Flow$-239.1M$-239.1M$-211.2M$-248.9M$-186.6M
Returns
ROE-49.9%-49.9%-1252.8%15.5%25.7%
Growth & Yield
Revenue Growth83.4%83.4%30.4%65.8%—
EPS Growth77.4%77.4%-48.3%20.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.